The original drug Polyoxidonium® (azoximer bromide) has been added to the updated Temporary Anti-COVID-19 Guidelines of the Russian Ministry of Health for the prevention, diagnosis and treatment of the novel coronavirus infection. According to the document, azoximer bromide is indicated for non-specific drug prevention of COVID-19.
In the fall of 2023, Russian authorities record a significant increase in COVID-19 incidence again, with the number of detected cases having increased by 15% over the past week, as reported by the Federal Response Center.
On October 26, 2023, the Ministry of Health approved revised temporary Anti-COVID-19 Guidelines No. 18 by adding Polyoxidonium® thereto.
The Russian drug developed by Petrovax Pharm was added to the document upon successful data from the meta-analysis titled “Experience of Using Azoximer Bromide for the Prevention of Acute Respiratory Infections and COVID-19 in Adults in High-Risk Groups (Red Zone Medical Workers)”, which covered 1,141 participants aged 18 to 69 years.
Doctors in the red zone who received Polyoxidonium® as prevention therapy showed greater resistance to infection, and COVID-19 was diagnosed in them 3 times less often than in the control group. The study also noted a favorable tolerability profile for the drug.
The main indications of Polyoxidonium are the prevention and treatment of acute respiratory viral infections and influenza in adults and children aged 3 years or older. Clinical trials of the drug for the prevention and treatment of COVID-19 began at the peak of the pandemic in 2020. In the same year, Slovakia included it in its COVID-19 treatment recommendations. The drug is also added to the FMBA Guidelines for the prevention and treatment of influenza and other acute respiratory viral infections during the COVID-19 pandemic, in addition to the Flu in Adults clinical recommendations of the Russian Ministry of Health. Polyoxidonium® is also on the list of Vital and Essential Drugs and is widely used in Russia and abroad, including the EU.#COVID #Recommendations #Ministry of Health #Polyoxidonium
3 Dosage form: tablets